-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Axogen, Lowers Price Target to $50

Benzinga·10/23/2026 13:23:07
Barclays analyst Christopher Pasquale maintains Axogen (NASDAQ:AXGN) with a Overweight and lowers the price target from $55 to $50.